Plasmid DNA containing multiple CpG motifs triggers a strong immune response to hepatitis B surface antigen when combined with incomplete Freund's adjuvant but not aluminum hydroxide

Luo,Zichao; Shi,Huashan; Zhang,Hailong; Li,Meng; Zhao,Yuwei; Zhang,Jing; Guo,Fuchun; Luo,Shan; Sun,Ping; Zhang,Dongmei; Qian,Zhiyong; Yang,Li

doi:10.3892/mmr.2012.1079

Plasmid DNA containing multiple CpG motifs triggers a strong immune response to hepatitis B surface antigen when combined with incomplete Freund's adjuvant but not aluminum hydroxide

Authors:
- Zichao Luo
- Huashan Shi
- Hailong Zhang
- Meng Li
- Yuwei Zhao
- Jing Zhang
- Fuchun Guo
- Shan Luo
- Ping Sun
- Dongmei Zhang
- Zhiyong Qian
- Li Yang
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: September 12, 2012 https://doi.org/10.3892/mmr.2012.1079
Pages: 1309-1314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adjuvants are important components of recombinant protein vaccines which are often poorly immunogenic. For decades, the search for new vaccine adjuvants has been predominantly empirical. In addition, combinations of more than one adjuvant plus antigen have been systematically studied. Plasmid DNA containing additional oligodeoxynucleotides with unmethylated CpG motifs (CpG ODN) entrapped in liposomes has been used as an adjuvant for DNA vaccines and has shown powerful immunostimulatory functions. In our study, the combination of plasmid DNA containing 16 additional CpG ODNs (pv-16CpG) and aluminum hydroxide (AL) or incomplete Freund's adjuvant (IFA) was used as an adjuvant for a hepatitis B surface antigen (HBsAg) vaccine to immunize C57BL/6J mice. ELISA and ELISPOT assays were used to analyze the immunological effects of the novel vaccine. A significant enhancement of the anti-HBs titer and seroconversion was observed when the CpG plasmid was combined with IFA, but not with AL. In addition, anti-HBs antibody isotype analysis revealed that the combination of CpG plasmid and IFA induced a strong HBsAg-specific IgG2a response. Moreover, the ELISPOT assays suggested that pv-16CpG suspended in IFA evoked a strong T helper 1 (Th1) immune response and high IFN-γ production. These results demonstrate that pv-16CpG suspended in IFA is able to induce cellular and humoral immune responses to HBsAg, and confirm its potential as an adjuvant for use in protein vaccines.

View Figures

View References

1	Weeratna RD, McCluskie MJ, Xu Y and Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:1755–1762. 2000. View Article : Google Scholar : PubMed/NCBI
2	Ulmer JB, Valley U and Rappuoli R: Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 24:1377–1383. 2006. View Article : Google Scholar : PubMed/NCBI
3	Aguilar JC and Rodriguez EG: Vaccine adjuvants revisited. Vaccine. 25:3752–3762. 2007. View Article : Google Scholar : PubMed/NCBI
4	Gupta RK and Siber GR: Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 13:1263–1276. 1995. View Article : Google Scholar : PubMed/NCBI
5	O’Hagan DT and De Gregorio E: The path to a successful vaccine adjuvant - ‘the long and winding road’. Drug Discov Today. 14:541–551. 2009.
6	Stacey KJ and Blackwell JM: Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun. 67:3719–3726. 1999.PubMed/NCBI
7	Jones TR, Obaldia N III, Gramzinski RA, et al: Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 17:3065–3071. 1999. View Article : Google Scholar
8	Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS and Klinman DM: Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 162:2291–2298. 1999.PubMed/NCBI
9	Moldoveanu Z, Love-Homan L, Huang WQ and Krieg AM: CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:1216–1224. 1998. View Article : Google Scholar : PubMed/NCBI
10	Klinman DM, Yi AK, Beaucage SL, Conover J and Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA. 93:2879–2883. 1996. View Article : Google Scholar : PubMed/NCBI
11	Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA and Davis HL: CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 95:15553–15558. 1998.PubMed/NCBI
12	Corr M, Lee DJ, Carson DA and Tighe H: Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 184:1555–1560. 1996. View Article : Google Scholar : PubMed/NCBI
13	Kojima Y, Xin KQ, Ooki T, et al: Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine. 20:2857–2865. 2002. View Article : Google Scholar : PubMed/NCBI
14	Klinman DM, Barnhart KM and Conover J: CpG motifs as immune adjuvants. Vaccine. 17:19–25. 1999. View Article : Google Scholar : PubMed/NCBI
15	Zhang XP, Yang L, Shi HS, et al: An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complexes elicits a protective immune response against murine colon carcinoma. Cancer Biol Ther. 10:276–281. 2010. View Article : Google Scholar
16	Wagner H: Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 73:329–368. 1999. View Article : Google Scholar : PubMed/NCBI
17	Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:709–760. 2002. View Article : Google Scholar : PubMed/NCBI
18	Tudor D, Dubuquoy C, Gaboriau V, Lefèvre F, Charley B and Riffault S: TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine. 23:1258–1264. 2005. View Article : Google Scholar : PubMed/NCBI
19	Spies B, Hochrein H, Vabulas M, et al: Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol. 171:5908–5912. 2003. View Article : Google Scholar : PubMed/NCBI
20	Gurunathan S, Klinman DM and Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 18:927–974. 2000. View Article : Google Scholar : PubMed/NCBI
21	Cox JC and Coulter AR: Adjuvants-a classification and review of their modes of action. Vaccine. 15:248–256. 1997. View Article : Google Scholar : PubMed/NCBI
22	Weeratna R, Comanita L and Davis HL: CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol. 81:59–62. 2003. View Article : Google Scholar : PubMed/NCBI
23	Mancino D and Ovary Z: Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgG1 antibody production in different inbred mouse strains. Int Arch Allergy Appl Immunol. 61:253–258. 1980. View Article : Google Scholar : PubMed/NCBI
24	Jensen FC, Savary JR, Diveley JP and Chang JC: Adjuvant activity of incomplete Freund’s adjuvant. Adv Drug Deliv Rev. 32:173–186. 1998.
25	Billiau A and Matthys P: Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 70:849–860. 2001.
26	Liaw YF and Chu CM: Hepatitis B virus infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zuckerman JN: Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 78:169–177. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kovacs-Nolan J, Latimer L, Landi A, et al: The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine. 27:2055–2064. 2009. View Article : Google Scholar : PubMed/NCBI
29	Perrie Y, Mohammed AR, Kirby DJ, McNeil SE and Bramwell VW: Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 364:272–280. 2008. View Article : Google Scholar : PubMed/NCBI
30	Harandi AM, Medaglini D and Shattock RJ; Working Group convened by EUROPRIS. Vaccine adjuvants: a priority for vaccine research. Vaccine. 28:2363–2366. 2010. View Article : Google Scholar : PubMed/NCBI
31	Lindblad EB: Aluminium compounds for use in vaccines. Immunol Cell Biol. 82:497–505. 2004. View Article : Google Scholar : PubMed/NCBI
32	Sun S, Kishimoto H and Sprent J: DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med. 187:1145–1150. 1998. View Article : Google Scholar : PubMed/NCBI
33	Shirodkar S, Hutchinson RL, Perry DL, White JL and Hem SL: Aluminum compounds used as adjuvants in vaccines. Pharm Res. 7:1282–1288. 1990. View Article : Google Scholar : PubMed/NCBI
34	al-Shakhshir RH, Regnier FE, White JL and Hem SL: Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 13:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
35	Gürsel M, Tunca S, Ozkan M, Ozcengiz G and Alaeddinoglu G: Immunoadjuvant action of plasmid DNA in liposomes. Vaccine. 17:1376–1383. 1999.PubMed/NCBI
36	Bachmann MF and Jennings GT: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 10:787–796. 2010. View Article : Google Scholar : PubMed/NCBI